The relationship between testosterone and prostate cancer, testosterone replacement therapy, and tools for predicting cancer aggressiveness and guiding therapy | Ted Schaeffer, M.D., Ph.D.
The podcast episode focuses on the topic of testosterone and prostate cancer, specifically discussing the TRAVERSE trial. The TRAVERSE study looked at men who were hypogonadal and aimed to replete their testosterone levels to a eugonadal level. The study found that supplementation of endogenous testosterone with exogenous testosterone did not increase the risk of being diagnosed with prostate cancer. Men with low PSA levels have a low risk of being diagnosed with prostate cancer, and changes in PSA levels can be used to monitor for potential risks when supplementing with exogenous testosterone.